NBP
NASDAQNovaBridge Biosciences
News25/Ratings1
Price$1.27-0.02 (-1.55%)
01:30 PM07:45 PM
News · 26 weeks44-44%
2026-04-192026-10-11
Mix2190d
- SEC Filings7(33%)
- Other6(29%)
- Insider6(29%)
- Earnings1(5%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRHiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater ChinaHiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ:NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis showed 50% complete corneal healing in the highest dose cohort after an 8-week courseHT006.2.2 is designed to offer a more convenient treatment option for patients with neurotrophic keratitis, building on Hiteck's longstanding expertise in nerve growth factor (NGF) therapeuticsWUHAN, China, Oct. 13, 2026 /PRNewswire/ -- Wuhan Hiteck Biological Pharma Co., Ltd. ("Hiteck") (SZSE: 300683) today announced
- PRVisara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic KeratitisVisara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2 Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage program, expanding the Company's ophthalmology portfolio beyond retinal vascular disease into ocular surface disease HT006.2.2 is designed to offer a more convenient treatment option for patients with neurotrophic keratitis ROCKVILLE, Md., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Visara, Inc. ("Visara" or the "Company"), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences ("NovaBridge") (NASDAQ:NBP), today announced that it has entered into an exclusive license agre
- PRNovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in participants with previously untreated, HER2-negative, CLDN18.2-positive, and PD-L1-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (GEA), will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. ESMO Congress 2026 is scheduled to take place October 23-27, 2026, in Madrid, Spain. "Patients with metastatic gastroesophageal adenocarcinoma c
- INSIDERChief Medical Officer Dennis Phillip Andrew converted options into 23,695 units of Ordinary Shares and sold $5,828 worth of Ordinary Shares (8,209 units at $0.71), increasing direct ownership by 10% to 173,427 units (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERChief Bus. Development Officer Cao Sean Wuxiong sold $79,904 worth of Ordinary Shares (107,978 units at $0.74), decreasing direct ownership by 29% to 266,467 units (SEC Form 4) (for tax liability)4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dewhurst Martin William3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERChief Bus. Development Officer Cao Sean Wuxiong converted options into 339,372 units of Ordinary Shares, increasing direct ownership by 968% to 374,445 units (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent DirectorMartin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced the appointment of Martin Dewhurst to its Board of Directors (the "Board") as an independent director, and as a member of both the Audit Committee and the Compensation Committee, e
- INSIDEREVP, Clinical Development Xu Cong Claire converted options into 9,382 units of Ordinary Shares and sold $2,593 worth of Ordinary Shares (3,282 units at $0.79), increasing direct ownership by 2% to 304,201 units (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- PRNovaBridge Biosciences to Participate in September Investor ConferencesROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026: Conference details: Cantor 2026 Global Healthcare ConferenceFormat: Fireside Chat and one-on-one meetingsPresenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge BiosciencesDate: Thursday, September 10, 2026Time: 1:00 PM ETWebcast Link: Here H.C. Wainwright 28th Annual Global I
- INSIDERDirector Lenz Robert A. converted options into 17,218 units of Ordinary Shares (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic ExecutionExecuting NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholdersAppointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the CompanyAdvancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval PathwayProgressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durabilityMaintained a strong balance sheet with $215.9 million in cash, cash equivalents, short-term investments, and equity investment
- SECSEC Form S-8 filed by NovaBridge BiosciencesS-8 - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026. Webcast Information: Date: Thursday, August 20, 2026Time: 9:00 AM ET/9:00 PM China Standard TimeWeb Access - China: Click hereWebcast Access – All other locations: Click here The live and archived w
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026ROCKVILLE, Md., July 24, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced that it will hold its annual general meeting of shareholders (the "AGM") at NovaBridge Biosciences Shanghai office, 38F, AIA Tower, No. 866 Dongchangzhi Road, Shanghai, China on September 8, 2026 at 10:00 a.m. (Shanghai time). Holders of record of ordinary shares of a par value of US$0.0001 each of the Company at the close of business on July 27, 2026 (Shanghai time) are entitled to notice of, to attend and to vote at, the AGM or any adjournment(s
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Hagler Mark Arnold4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Lin Liwei Lorraine4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Gupta Srishti4 - NovaBridge Biosciences (0001778016) (Issuer)
NBP FAQ
6 questionsWhere does NBP stock trade?
NovaBridge Biosciences (NBP) is listed on NASDAQ.What sector and industry is NBP in?
NovaBridge Biosciences operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NovaBridge Biosciences go public?
NovaBridge Biosciences (NBP) completed its IPO in 2020.What are analysts saying about NBP?
NovaBridge Biosciences has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2026-02-06. Recent price targets cluster around $900.00.What companies are similar to NBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NBP side-by-side with any of them on Quantisnow.How can I track NBP on Quantisnow?
Quantisnow aggregates NovaBridge Biosciences's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NBP to receive live email and push alerts on every new disclosure.